Thursday, 12 August 2021

A Histopathological Study of Proton Pump Inhibitors: Are They Safe on Kidneys? | Chapter 14 | Technological Innovation in Pharmaceutical Research Vol. 9

 Background: PPI is used in between 45 and 85 percent of instances in India. In 82.96 percent of cases, patients with chronic renal illness were prescribed a PPI. Recent case reports, however, suggest that PPI can cause AIN. Because many patients take many drugs, it's tough to estimate the exact rate of this uncommon side effect, making establishing a causal relationship between AIN and PPI much more challenging. Early detection of AIN and withdrawal of the offending medicine may delay the progression of AIN to end-stage chronic renal disease. As a result, we decided to conduct research to see if there is a link between PPI and AIN. The goal of the study was to see what effect concomitant usage of PPI and NSAID or AMA had on the histopathology of experimental animals. The goal was to use histopathological investigations to determine the effect of simultaneous treatment of PPI with NSAIDS/antimicrobials on kidneys and compare it to a normal histological picture to see what changes had occurred due to medication administration. The rats used in the experiment weighed between 150 and 250 grammes. Omeprazole, Three groups were given pantoprazole, rabeprazole, and diclofenac for 28 days: group A received nothing, group B received diclofenac, and group C received ofloxacin. The animals with disturbed RFTs were grouped together after the 28th day. Two animals were sacrificed for each group. Their histopathology tests were also finished. The RFTs of at least three rats in each group were found to be aberrant. And, whether or not AIN is used, the majority of histopathological studies show structural and vascular changes. Conclusions: PPIs alone are known to cause AIN, but when other nephrotoxic medications are taken, the risk of AIN increases.

Author(s) Details

Dr. Ramachandra Prabhakar Limay
Department of Pharmacology, Bharati Vidyapeeth (Deemed to University), Medical College and Hospital, Sangli, Maharashtra, India.

Dr. Shabbir Rafik Pendhari
Department of Pharmacology, Bharati Vidyapeeth (Deemed to University), Medical College and Hospital, Sangli, Maharashtra, India.

Kedar Shashikant Joshi
Hanul Medizin Pvt Ltd, Pune, Maharashtra, India.

View Book :-  https://stm.bookpi.org/TIPR-V9/article/view/2527

No comments:

Post a Comment